EMAEMA-Gate: PharmaMar wins suit against EMAThe European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin. more ➔
Financing roundNovo Holdings and Abingworth co-lead £90m financing in Myricx Bio LtdDanish Novo Holdings A/S and Abingworth co-led the largest European Series A financing round this year. Together with existing and new investors, they put £90m into cancer ADC specialist Myricx Bio … more ➔
AcquisitionAnacura aquires Ohmx.bioMerger within Ghent, Belgium: Anacura acquires OHMX.bio (both residing in neighborhood), adding multi-omics for drug discovery and diagnostics to its services. more ➔
EMATen drug recommendations by EMA EMA’s human medicines committee (CHMP) recommended ten medicines for approval at its June 2024 meeting. more ➔
Nyoxoa SANyxoah signs a €37.5m loan with the European Investment BankNyxoah SA (Euronext Brussels/Nasdaq: NYXH), located in Mont-Saint-Guibert, Belgium announced that it has signed a €37.5m loan facility agreement with the European Investment Bank (“EIB”). The agreement … more ➔
ExpansionNovo Nordisk expands footprint in USA Novo Nordisk realises a major expansion in Clayton, NC (USA). The project will enhance Novo Nordisk’s manufacturing capabilities with more than 1.4 million square feet of new space. more ➔
InvestmentForbion closes first Bioeconomy Fund with US$75m Forbion BioEconomy represents a strategic expansion of Forbion’s investment scope in biotech and in the life sciences sector to address challenges relating to the environment, the growing need for a … more ➔
Drug deliveryNo more needles – Exvolvo arises with help of Verily and NLC Health NLC Health Ventures (Amsterdam, The Netherlands), in partnership with Verily, the precision health technology daughter company of Alphabet/Google, will launch Exolvo Biosciences, a pioneering biotech … more ➔
ChikungunyaValneva gets approval for Chikungunya vaccine in Canada Valneva announces Health Canada approval of the world’s first chikungunya vaccine, IXCHIQ®. more ➔
Tubulis GmbHTubulisTubulis from Munich doses first Patient with own ADC linker technologyTubulis doses first patient in phase 1/2a trial investigating ADC candidate TUB-040 in ovarian cancer and lung adenocarcinoma (NSCLC). TUB-040 is a NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary … more ➔
Tubulis GmbH